Shukra Pharmaceuticals Limited

NSE: SHUKRAPHAR

29

total announcements

SHUKRAPHAR.NS · 15 min delayed

Key Stats · Yahoo Finance · as of 19 Nov 2026

Market Cap

₹3,638 Cr

P/E (TTM)

81.4

EPS (TTM)

₹1.01

52W Low

₹40.06

52W High

₹84.80

Dividend Yield

0.01%

Beta

0.55

Price / Book

30.4

Return on Equity

48.08%

Debt / Equity

19.0

Revenue (TTM)

₹111 Cr

Gross Margin

75.31%

Operating Margin

57.88%

NSEName and Symbol Changename_and_symbol_change1d ago

Shukra Pharmaceuticals Limited

Name and Symbol Change

Shukra Pharmaceuticals Limited will change its name to Shukra Medtech Limited and symbol from SHUKRAPHAR to SHUKRAMED, effective November 20, 2026.

Read more →📎 1 attachment
NSEName Changename_change2d ago

Shukra Pharmaceuticals Limited

Name Change

Shukra Pharmaceuticals Limited has informed the Exchange that the name has been changed from Shukra Pharmaceuticals Limited to Shukra Medtech Limited, with the new name and symbol to be effective from November 20, 2026.

Read more →📎 1 attachment
NSEPress ReleaseResults6 Nov 2026

Shukra Pharmaceuticals Limited

Press Release

Shukra Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 06, 2026, titled "Newspaper Publication of Quarterly Results".

Read more →📎 1 attachment
NSEPress Release▲ PositiveResults5 Nov 2026

Shukra Pharmaceuticals Limited

Press Release

Shukra Pharmaceuticals Limited has reported a significant increase in revenue and net profit for the quarter and six months ended 30 September 2026. The company's revenue from operations stood at ₹44.20 crore, compared with ₹5.88 crore in the same period last year, with a 652% year-over-year growth. The net profit rose to ₹16.01 crore from ₹2.38 crore, with a 573% year-over-year growth. The company's management has attributed the growth to its expansion into the overseas market, particularly in the MedTech segment.

Read more →📎 1 attachment
NSEStatement of deviation(s) or variation(s) under Reg. 32Results4 Nov 2026

Shukra Pharmaceuticals Limited

Statement of deviation(s) or variation(s) under Reg. 32

Shukra Pharmaceuticals Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32, confirming no deviation or variation in the utilization of proceeds from the object mentioned in the notice of Extra Ordinary general meeting for issuance of convertible warrants on a preferential basis.

Read more →📎 1 attachment
NSEOutcome of Board MeetingResults4 Nov 2026

Shukra Pharmaceuticals Limited

Outcome of Board Meeting

Shukra Pharmaceuticals Limited has submitted its unaudited financial results for the quarter and half year ended September 30, 2026, showing a net profit of ₹1,601.20 lakhs.

Read more →📎 1 attachment
NSEGeneral UpdatesRegulatory19 Oct 2026

Shukra Pharmaceuticals Limited

General Updates

Shukra Pharmaceuticals Limited has submitted a revised Chartered Accountant Certificate dated September 16, 2026, in connection with the final application for the change of name from 'SHUKRA PHARMACEUTICALS LIMITED' to 'SHUKRA MEDTECH LIMITED' and the consequent change in symbol.

Read more →📎 1 attachment
NSEStructural Digital Database17 Oct 2026

Shukra Pharmaceuticals Limited

Structural Digital Database

Shukra Pharmaceuticals Limited has submitted its Structured Digital Database (SDD) Compliance Certificate for the quarter ended September 30, 2026, confirming that the company has a SDD in place, with controls in place to access the database, and that all unpublished price sensitive information (UPSI) has been captured in the database.

Read more →📎 1 attachment
NSEGeneral Updatesname_change12 Oct 2026

Shukra Pharmaceuticals Limited

General Updates

Shukra Pharmaceuticals Limited has informed the Exchange about General Updates, specifically the change of name from 'SHUKRA PHARMACEUTICALS LIMITED' to 'SHUKRA MEDTECH LIMITED' as approved by the Ministry of Corporate Affairs (MCA).

Read more →📎 1 attachment
NSECertificate under SEBI (Depositories and Participants) Regulations, 201810 Oct 2026

Shukra Pharmaceuticals Limited

Certificate under SEBI (Depositories and Participants) Regulations, 2018

Shukra Pharmaceuticals Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities and listing of shares on stock exchanges.

Read more →📎 1 attachment
NSEOutcome of Board MeetingResults6 Oct 2026

Shukra Pharmaceuticals Limited

Outcome of Board Meeting

Shukra Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on October 06, 2026, where the Board of Directors approved the allotment of 17,35,000 fully paid-up equity shares to promoters upon conversion of warrants into equity shares.

Read more →📎 1 attachment
NSEGeneral UpdatesRegulatory6 Oct 2026

Shukra Pharmaceuticals Limited

General Updates

Shukra Pharmaceuticals Limited has informed the Exchange about General Updates, clarifying that there is no unannounced material information or pending price-sensitive announcement that could influence the trading volume or price behavior of the Company's shares, attributing the recent spurt in the share price to market driven conditions and natural trading dynamics.

Read more →📎 1 attachment
NSEPrice movementRegulatory6 Oct 2026

Shukra Pharmaceuticals Limited

Price movement

Shukra Pharmaceuticals Limited's stock has experienced significant price movement, prompting the NSE to contact the company for clarification, awaiting response.

NSEShareholders meetingshareholders_meeting29 Sept 2026

Shukra Pharmaceuticals Limited

Shareholders meeting

Shukra Pharmaceuticals Limited has submitted the Exchange a copy Scrutinizers report of Postal Ballot. The company has informed the Exchange regarding voting results of the resolutions passed in the meeting.

Read more →📎 1 attachment
NSEOutcome of Board Meeting28 Sept 2026

Shukra Pharmaceuticals Limited

Outcome of Board Meeting

Shukra Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on September 28, 2026. The 33rd Annual General Meeting (AGM) of the Company was held through video conferencing, in compliance with the applicable provisions of the Companies Act, 2013, and SEBI circulars.

Read more →📎 1 attachment
NSETrading Window24 Sept 2026

Shukra Pharmaceuticals Limited

Trading Window

Shukra Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Read more →📎 1 attachment
NSERecord DateDividend18 Sept 2026

Shukra Pharmaceuticals Limited

Record Date

Shukra Pharmaceuticals Limited has announced the record date for determining the eligibility of members to receive the final dividend for the financial year ended 31 March 2026.

Read more →📎 1 attachment
NSEShareholders meetingResults5 Sept 2026

Shukra Pharmaceuticals Limited

Shareholders meeting

Shukra Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 28, 2026, to consider and adopt audited financial statements for the financial year ended March 31, 2026, approve and declare final dividend, re-appoint a director, and regularize the appointment of an additional independent director.

Read more →📎 1 attachment
NSEGeneral Updates3 Sept 2026

Shukra Pharmaceuticals Limited

General Updates

Shukra Pharmaceuticals Limited has rescheduled its 33rd Annual General Meeting (AGM) to September 28, 2026, due to unavoidable administrative exigencies. The revised book closure dates are September 22-28, 2026.

Read more →📎 1 attachment
NSEGeneral UpdatesDividend3 Sept 2026

Shukra Pharmaceuticals Limited

General Updates

Shukra Pharmaceuticals Limited has informed the Exchange about General Updates, specifically the Record Date for determining eligibility for Final Dividend for the financial year ended 31 March, 2026.

Read more →📎 1 attachment
Page 1 of 2Next →